DID YOU KNOW? DTIC has over 3.5 million final reports on DoD funded research, development, test, and evaluation activities available to our registered users. Click
HERE to register or log in.
Accession Number:
ADA604489
Title:
Novel Biomarker Discovery for Diagnostic and Therapeutic Strategies in Prostate Cancer
Descriptive Note:
Annual rept. 1 Mar 2012-28 Feb 2013
Corporate Author:
MIAMI UNIV FL MILLER SCHOOL OF MEDICINE
Report Date:
2013-03-01
Pagination or Media Count:
9.0
Abstract:
The purpose of this grant is to identify, isolate and characterize high affinity aptamers that distinguish between prostate cancers that are likely to remain organ-confined and those with potential to metastasize, The scope of this pilot is to generate DNA aptamers that selectively react with a prostate cancer cell line that remains confined to the prostate LNCaP vs. a subpopulation of this cell line that has acquired the ability to metastasize aggressively, employing Cell-Selex and Aptamer-Facilitated Biomarker Discovery AptaBiD technology. Major Findings and Progress 1 Non-metastatic LNCaP-Pro-5 cells and metastatic LNCaP-LN3 cells have been provided by Curtis Pettaway, M.D. Anderson Cancer Center, Houston, Texas. 2 Parental LNCaP cells have been obtained from American Type Culture Collection. 3 Phenotypic validation aggressive vs. indolent growth has been carried out on all cell lines using the Boyden Chamber assay. 4 DNA 40 bp aptamer libraries have been generated. 5 The first of 8 rounds of Cell-Selex has been initiated. 6 Plan for next-generation sequencing and bioinformatic analysis pathway has been established to yield desired phenotype-specific DNA aptamers. Next steps will include completion of Cell-Selex, NexGen sequencing and testing of DNA aptamer families on human clinical prostate cancer specimens.
Distribution Statement:
APPROVED FOR PUBLIC RELEASE
